Leptomycin B has shown severe toxicity in vitro as it binds irreversibly to XPO1, therefore selinexor monotherapy was implemented in NPM1-mutated AML patients; however, selinexor has shown only temporary and insignificant clinical benefits due to its high toxicity [142]. Here, NPM1 is linked to acute myeloid leukemia.